← All stocks

Wave Life Sciences, Inc.

WVE Net buying
CIK 0001631574 #2524 in the set updated 17 Sep 2026
Bought (120 mo)
$166.66M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$58.80M
$6.13M on a plan · $37.39M straight out of an exercise
Sold at will
$15.28M
50 of 144 sales
Net
+$107.86M
+$151.38M against sales at will

By person

19 insiders · 166 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
Director
$99.89M (10)
+$99.89M
34,549,118
17.53%
$182.76M
+153.8%
GSK plc entity
10% owner
$66.77M (3)
+$66.77M
18,245,691
9.26%
$96.52M
+70.8%
BOLNO PAUL
President and CEO
$15.80M (30) scheduled
−$15.80M
275,520
0.1398%
$1.46M
+44.4%
Francis Chris
See Remarks
$15.78M (34) scheduled
−$15.78M
61,867
0.0314%
$327.28K
Tanaka Masaharu
Director
$11.31M (3)
−$11.31M
2,774,118
1.41%
$14.68M
−14.1%
Moran Kyle
Chief Financial Officer
$4.67M (14) scheduled
−$4.67M
134,385
0.0682%
$710.90K
+1,398%
Verdine Gregory L.
Director
$2.08M (9)
−$2.08M
275,217
0.1397%
$1.46M
+223.6%
Tan Aik Na
Director
$2.03M (11) scheduled
−$2.03M
24,968
0.0127%
$132.08K
Regnante Keith
Chief Financial Officer
$1.69M (3) scheduled
−$1.69M
29,186
0.0148%
$154.39K
Panzara Michael A.
See Remarks
$1.68M (11) scheduled
−$1.68M
109,103
0.0554%
$577.15K
+379.6%
HENRY CHRISTIAN O
Director
$1.56M (6) scheduled
−$1.56M
12,700
0.0064%
$67.18K
Vargeese Chandra
See Remarks
$879.54K (12) scheduled
−$879.54K
408,246
0.2072%
$2.16M
+1,438%
Rawcliffe Adrian
Director
$806.60K (3) scheduled
−$806.60K
0
0.0000%
$0.00
Wagner Heidi L
Director
$231.07K (3) scheduled
−$231.07K
44,930
0.0228%
$237.68K
CORRIGAN MARK
Director
$217.30K (2) scheduled
−$217.30K
28,815
0.0146%
$152.43K
TAKANASHI KEN
Director
$65.85K (2) scheduled
−$65.85K
9,626,487
4.89%
$50.92M
+68.7%
Gaiero David G
Interim CFO
$4.56K (1)
−$4.56K
6,392
0.0032%
$33.81K
−9.2%
Baldry Mark
Chief Commerical Officer
39,000
0.0198%
$206.31K
GUERCIOLINI ROBERTO
See Remarks
4,000
0.0020%
$21.16K
Insider
Date
Role
Action
Shares
Price
Amount
Wagner Heidi L
11 Aug 2026
Director
Sold after exercise
7,000
$6.01
$42.07K
Francis Chris
26 Feb 2026
See Remarks
Sold after exercise
15,294
$15.00
$229.41K
Francis Chris
26 Feb 2026
See Remarks
Sold after exercise
17,900
$15.09
$270.18K
Francis Chris
2 Jan 2026
See Remarks
Sold after exercise
1,295
$16.70
$21.63K
Francis Chris
2 Jan 2026
See Remarks
Sold after exercise
8,080
$15.92
$128.63K
Moran Kyle
9 Dec 2025
Chief Financial Officer
Sold after exercise
50,000
$20.03
$1.00M
Moran Kyle
9 Dec 2025
Chief Financial Officer
Sold after exercise
36
$20.25
$729.00
Moran Kyle
8 Dec 2025
Chief Financial Officer
Sold after exercise
50,000
$18.00
$900.00K
Moran Kyle
8 Dec 2025
Chief Financial Officer
Sold after exercise
50,000
$13.20
$660.00K
Moran Kyle
8 Dec 2025
Chief Financial Officer
Sold after exercise
50,000
$15.00
$750.00K
Moran Kyle
8 Dec 2025
Chief Financial Officer
Sold after exercise
60,000
$13.20
$792.00K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
22,500
$14.08
$316.80K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
50,000
$16.00
$800.00K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
122,349
$14.20
$1.74M
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
17,900
$15.00
$268.50K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
37,500
$14.08
$528.00K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
9,375
$15.00
$140.63K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
45,882
$14.50
$665.29K
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
107,400
$14.56
$1.56M
Francis Chris
8 Dec 2025
See Remarks
Sold after exercise
28,125
$14.50
$407.81K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
21,000
$12.75
$267.75K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
21,000
$12.75
$267.75K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
25,000
$15.00
$375.00K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
20,000
$12.75
$255.00K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
17,230
$15.00
$258.45K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
15,000
$12.75
$191.25K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
7,494
$15.00
$112.41K
Tan Aik Na
8 Dec 2025
Director
Sold after exercise
7,494
$12.75
$95.55K
HENRY CHRISTIAN O
8 Dec 2025
Director
Sold after exercise
30,000
$18.02
$540.60K
HENRY CHRISTIAN O
8 Dec 2025
Director
Sold after exercise
15,000
$14.07
$211.05K
HENRY CHRISTIAN O
8 Dec 2025
Director
Sold after exercise
42,000
$12.75
$535.50K
HENRY CHRISTIAN O
8 Dec 2025
Director
Sold after exercise
6,445
$12.75
$82.17K
Wagner Heidi L
8 Dec 2025
Director
Sold after exercise
7,000
$14.00
$98.00K
Wagner Heidi L
8 Dec 2025
Director
Sold after exercise
7,000
$13.00
$91.00K
Rawcliffe Adrian
8 Dec 2025
Director
Sold after exercise
42,000
$15.00
$630.00K
Tan Aik Na
15 Aug 2025
Director
Sold after exercise
21,000
$9.25
$194.25K
HENRY CHRISTIAN O
20 Mar 2025
Director
Sold after exercise
10,500
$9.77
$102.57K
BOLNO PAUL
7 Mar 2025
President and CEO
Sold after exercise
169,025
$9.57
$1.62M
BOLNO PAUL
25 Nov 2024
President and CEO
Sold after exercise
50,000
$15.00
$750.00K
Francis Chris
8 Nov 2024
See Remarks
Sold after exercise
36,000
$16.00
$576.00K
Francis Chris
16 Oct 2024
See Remarks
Sold after exercise
22,500
$13.50
$303.75K
Francis Chris
16 Oct 2024
See Remarks
Sold after exercise
65,625
$13.75
$902.34K
Francis Chris
16 Oct 2024
See Remarks
Sold after exercise
40,997
$13.00
$532.96K
Francis Chris
16 Oct 2024
See Remarks
Sold after exercise
79,714
$14.00
$1.12M
BOLNO PAUL
15 Sep 2020
President and CEO
Sold after exercise
100,000
$15.00
$1.50M
BOLNO PAUL
25 Aug 2020
President and CEO
Sold after exercise
25,000
$12.00
$300.00K
BOLNO PAUL
2 Jul 2020
President and CEO
Sold after exercise
95,921
$10.27
$985.11K
BOLNO PAUL
2 Jul 2020
President and CEO
Sold after exercise
4,079
$10.91
$44.50K
BOLNO PAUL
2 Jul 2020
President and CEO
Sold after exercise
43,068
$10.26
$441.88K
BOLNO PAUL
2 Jul 2020
President and CEO
Sold after exercise
4,509
$10.82
$48.79K
Vargeese Chandra
3 Dec 2019
Senior VP, Drug Discovery
Sold after exercise
6,000
$35.00
$210.00K
BOLNO PAUL
15 Mar 2019
President and CEO
Sold after exercise
1,763
$46.00
$81.10K
BOLNO PAUL
15 Mar 2019
President and CEO
Sold after exercise
8,237
$45.22
$372.48K
BOLNO PAUL
15 Mar 2019
President and CEO
Sold after exercise
5,065
$45.89
$232.43K
BOLNO PAUL
15 Mar 2019
President and CEO
Sold after exercise
34,935
$45.45
$1.59M
Francis Chris
25 Sep 2018
See Remarks
Sold after exercise
10,543
$56.00
$590.41K
Vargeese Chandra
24 Sep 2018
Senior VP, Drug Discovery
Sold after exercise
3,000
$55.00
$165.00K
Regnante Keith
24 Sep 2018
Chief Financial Officer
Sold after exercise
29,500
$55.00
$1.62M
Francis Chris
24 Sep 2018
See Remarks
Sold after exercise
1,032
$56.00
$57.79K
Francis Chris
9 Jul 2018
See Remarks
Sold after exercise
596
$38.22
$22.78K
Francis Chris
9 Jul 2018
See Remarks
Sold after exercise
23,900
$37.25
$890.28K
Francis Chris
1 Jun 2018
See Remarks
Sold after exercise
24,496
$48.00
$1.18M
BOLNO PAUL
30 May 2018
President and CEO
Sold after exercise
20,250
$45.00
$911.25K
Francis Chris
30 May 2018
See Remarks
Sold after exercise
24,496
$45.50
$1.11M
BOLNO PAUL
29 May 2018
President and CEO
Sold after exercise
3,145
$45.00
$141.53K
BOLNO PAUL
25 May 2018
President and CEO
Sold after exercise
8,316
$45.00
$374.22K
BOLNO PAUL
2 May 2018
President and CEO
Sold after exercise
18,289
$45.00
$823.01K
Francis Chris
20 Feb 2018
See Remarks
Sold after exercise
11,504
$55.95
$643.65K
Francis Chris
16 Feb 2018
See Remarks
Sold after exercise
9,412
$55.00
$517.66K
Francis Chris
16 Feb 2018
See Remarks
Sold after exercise
723
$51.80
$37.45K
Panzara Michael A.
15 Feb 2018
Franchise Lead, Neurology
Sold after exercise
18,750
$50.00
$937.50K
Vargeese Chandra
15 Feb 2018
See Remarks
Sold after exercise
2,000
$50.00
$100.00K
Vargeese Chandra
23 Jan 2018
See Remarks
Sold after exercise
2,000
$40.00
$80.00K
Vargeese Chandra
22 Nov 2017
See Remarks
Sold after exercise
1,500
$35.00
$52.50K

What was left out

Form 4 filings counted 226
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 14
Sales on a Rule 10b5-1 plan 20
Sales straight out of an exercise 74
Sales at will 50
Transactions with no price 0
Shares from compensation/vesting 9,085,925
Sales filed before the plan box existed 46
History held since 14 Nov 2016